Drug Discovery World

JANUARY 31, 2024

The line-up of speakers is a reminder of how much insight there is in our community across academia, government agencies and industry – and the value of connecting these. At events such as SLAS2024, we are all reminded of how important it is to meet, network and innovate in order to facilitate growth.

Government 130

Government Vaccine Disease Science 130

The Pharma Data

OCTOBER 28, 2020

OSAKA, Japan–( BUSINESS WIRE )– Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), announced today that it will import and distribute 50 million doses of Moderna’s COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. President of the Global Vaccine Business Unit, Takeda.

Government 40

Government Vaccine Pharmaceutical Companies Pharmaceuticals 40

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S. Ugur Sahin, M.D.,

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

OCTOBER 6, 2021

Pfizer and BioNTech today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18?years years of age and older.

Vaccine 52

Vaccine Small Molecule Government Therapies 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer.

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Annaliesa is a world-class scientist with a track record of delivering both vaccines and therapeutics in pioneering new areas of science and where there is urgent unmet need.

Vaccine 40

Vaccine Research Doctors Laboratories 40

The Pharma Data

JANUARY 12, 2021

Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of the casirivimab and imdevimab antibody cocktail for use in non-hospitalized COVID-19 patients to meet the federal government’s Operation Warp Speed goals. million doses. . We are pleased to work with the U.S. In the U.S.

Government 52

Government Hospitals Virus Production 52

The Pharma Data

MAY 31, 2022

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda ( TSE:4502/NYSE:TAK ) announced to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax TM (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022. Moderna, Inc., ” Authorized Use.

Vaccine 52

Vaccine Marketing RNA Science 52

Drug Discovery World

NOVEMBER 24, 2023

The success of the Covid-19 vaccines should be a reminder that professionals from all corners of the world and from many disciplines can work together effectively and efficiently to achieve a common goal. Facing imminent threats, it’s easier to be motivated by common goals than be caught up in differences.

Research 147

Research Vaccine Science International 147

The Pharma Data

APRIL 18, 2022

Takeda today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid ® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.

Vaccine 52

Vaccine Clinical Trials Virus Government 52

The Pharma Data

AUGUST 7, 2020

Takeda now has a vaccine project in its fight against the COVID-19 pandemic, alongside repurposing existing drugs and developing a plasma-based therapy to treat the deadly disease. biotech’s coronavirus vaccine candidate, NVX-CoV2373, in Japan. RELATED: Novavax’s COVID-19 vaccine looks promising in early data.

Vaccine 52

Vaccine Therapies Government Treatment 52

The Pharma Data

DECEMBER 19, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. We look forward to vaccinations of this important population starting this week.”. government by the end of December 2020.

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

Drug Discovery World

MAY 6, 2024

A more established Amsterdam-based enterprise is gene therapy company uniQure, developer of etranacogene dezaparvovec, the first gene therapy for haemophilia B, which was approved for use in the US in November 2022 and in the EU in February 2023. The rights for etranacogene dezaparvovec were subsequently sold to CSL Pharmaceuticals.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

The Pharma Data

JUNE 24, 2021

This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine in this age group. COMIRNATY was the first COVID-19 vaccine to receive authorization in the EU and is the first to have its CMA extended to adolescents. g doses of the COVID-19 vaccine.

Vaccine 52

Vaccine Clinical Trials Trials FDA 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JULY 21, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union. This press release features multimedia.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 6, 2021

6 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the active immunisation of adults.

Vaccine 52

Vaccine Virus Clinical Trials Government 52

The Pharma Data

APRIL 15, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. About Pfizer: Breakthroughs That Change Patients’ Lives.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

MAY 6, 2021

Under the MoU, the companies and the IOC will coordinate with National Olympic Committees (NOCs) around the world to understand and work to help address the local need for vaccine doses for national delegations’ participation in the Games. We are proud to play a role in providing vaccines to athletes and national Olympic delegations.”.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Discovery World

OCTOBER 20, 2022

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research. . Government policies . Overview . Investment and collaboration .

Drugs 130

Drugs International Science Government 130

The Pharma Data

FEBRUARY 18, 2022

BioNTech SE (Nasdaq: BNTX, “BioNTech”) has taken a next step to improve vaccine supply in Africa. The company has introduced its approach to establishing scalable vaccine production by developing and delivering turnkey mRNA manufacturing facilities based on a container solution.

Vaccine 40

Vaccine Production Small Molecule Compliance 40

The Pharma Data

SEPTEMBER 12, 2020

Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

Vaccine 52

Vaccine Trials Clinical Trials Small Molecule 52

The Pharma Data

MARCH 23, 2023

Takeda has delivered plasma therapies to meet the needs of patients in Japan for more than 70 years. The company will unleash the power of automation and digitalization to deliver high quality products to patients reliant on PDTs, including those with diseases for which there are no alternative treatments.”

Therapies 40

Therapies Treatment Vaccine Production 40

The Pharma Data

MARCH 14, 2023

QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing. QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing.

Vaccine 40

Vaccine Virus Hospitals Trials 40

The Pharma Data

MAY 7, 2021

The Pfizer-BioNTech COVID-19 Vaccine is currently available in the U.S. Since then, the companies have delivered more than 170 million doses of the vaccine across the U.S. We are proud of the tremendous progress we’ve made since December in delivering vaccines to millions of Americans, in collaboration with the U.S.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

AUGUST 21, 2020

As the pharma community continue to research and develop hundreds of potential therapies to combat the Covid-19 pandemic, very few initiatives are yet to cross the finishing line into the commercial market. McKesson supports OWS to centralize distributor of future Covid-19 vaccines.

Vaccine 52

Vaccine Pharmacy Clinical Trials Virus 52

The Pharma Data

MARCH 5, 2021

Novartis announced today that it has signed an initial agreement to manufacture the mRNA and bulk drug product for the COVID-19 vaccine candidate CVnCoV from CureVac to aid in the fight against the COVID-19 pandemic. Preparations for the start of production, technology transfer and test runs are already underway.

Vaccine 52

Vaccine Production Biosimilars Hospitals 52

The Pharma Data

DECEMBER 11, 2020

FDA authorizes COVID-19 mRNA vaccine for emergency use; companies are prepared to deliver first doses in the U.S. Government to supply doses in 2020 & 2021. Food and Drug Administration (FDA) has authorized the emergency use of the mRNA vaccine, BNT162b2, against COVID-19 in individuals 16 years of age or older.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 10, 2020

–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. 11, 2020 02:48 UTC. CULVER CITY, Calif.–(

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

JULY 29, 2021

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines. HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. President of the Global Vaccine Business Unit, Takeda. 2 Norovirus is recognized as the leading cause of acute gastroenteritis across the age spectrum.

Vaccine 52

Vaccine Pharmaceutical Companies Clinical Trials Virus 52

The Pharma Data

APRIL 14, 2021

government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. government have agreed to modify the purchase agreement of bamlanivimab alone and focus on supply of bamlanivimab and etesevimab together. who require oxygen therapy due to COVID-19, OR.

Government 52

Government Long-Term Care Facilities Hospitals Treatment 52

The Pharma Data

MAY 7, 2021

. Pfizer-BioNTech files for US approval of COVID-19 vaccine ( Reuters ) ( NYTimes ) ( Politico ) ( Press ). Covid-19 Vaccines Are Wasted as Special Syringes Run Short ( WSJ ). Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug ( Endpoints ). What happens now?

Vaccine 52

Vaccine Compounding Pharmacies Regulations Drugs 52

The Pharma Data

NOVEMBER 20, 2020

billion doses by the end of 2021; the companies will be ready to distribute the vaccine within hours after authorization. BNT162b2 demonstrated a vaccine efficacy rate of 95%, with no serious safety concerns observed to date. by the middle to end of December 2020. participants are 56-85 years of age.

Vaccine 52

Vaccine FDA Clinical Trials Trials 52

The Pharma Data

SEPTEMBER 9, 2020

The vaccine supply for the EU would be produced by BioNTech’s manufacturing sites in Germany and Pfizer’s manufacturing site in Belgium. The proposed supply agreement with the European Commission would represent the largest initial order of vaccine doses for Pfizer and BioNTech to date. billion doses by the end of 2021.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

SEPTEMBER 30, 2021

Boehringer Ingelheim again joins efforts to fight rabies under this year’s theme for World Rabies Day by GARC: “Rabies: Facts, not Fear” Boehringer Ingelheim strives to raise awareness of the disease and its preventio. A disease like rabies, from which we will best protect humans by immunizing animals, is exemplary to spotlight that.

Vaccine 52

Vaccine Government Disease International 52

Elrig

MARCH 12, 2024

Steve’s Keynote: Supporting the UK’s globally competitive innovation ecosystem There is a fundamental shift in how life science research is being carried out, the computational tools are transforming early drug discovery which in turn leads to real chemistry, advanced diagnostics and innovative therapies.

Research 52

Research Science Government Engineering 52